首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2030591篇
  免费   160852篇
  国内免费   28584篇
耳鼻咽喉   24437篇
儿科学   60096篇
妇产科学   50121篇
基础医学   277660篇
口腔科学   54498篇
临床医学   199668篇
内科学   374811篇
皮肤病学   42451篇
神经病学   146850篇
特种医学   76982篇
外国民族医学   466篇
外科学   286630篇
综合类   107402篇
现状与发展   90篇
一般理论   560篇
预防医学   148810篇
眼科学   50077篇
药学   162023篇
  425篇
中国医学   28452篇
肿瘤学   127518篇
  2021年   26823篇
  2020年   22021篇
  2019年   24857篇
  2018年   31665篇
  2017年   26570篇
  2016年   26994篇
  2015年   35315篇
  2014年   46578篇
  2013年   56431篇
  2012年   80150篇
  2011年   86325篇
  2010年   53690篇
  2009年   47678篇
  2008年   72080篇
  2007年   75142篇
  2006年   74620篇
  2005年   71042篇
  2004年   62820篇
  2003年   59740篇
  2002年   55781篇
  2001年   99204篇
  2000年   100725篇
  1999年   84105篇
  1998年   23700篇
  1997年   21081篇
  1996年   20185篇
  1995年   20227篇
  1994年   18255篇
  1993年   15939篇
  1992年   59366篇
  1991年   57062篇
  1990年   54487篇
  1989年   52033篇
  1988年   47189篇
  1987年   45866篇
  1986年   42936篇
  1985年   40527篇
  1984年   29591篇
  1983年   25042篇
  1982年   13939篇
  1979年   25569篇
  1978年   17585篇
  1977年   14891篇
  1976年   13857篇
  1975年   14537篇
  1974年   17632篇
  1973年   16937篇
  1972年   15693篇
  1971年   14452篇
  1970年   13433篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty.  相似文献   
3.
4.
目的 探讨集束化干预策略联合闭环管理模式对ICU多重耐药菌感染的防控效果。方法选取2020年1~12月EICU住院患者275例作为对照组,实施常规管理;2021年1~10月EICU住院患者239例作为观察组,在常规管理基础上实施集束化干预策略联合闭环管理。结果实施后,观察组多重耐药菌感染发生率明显低于对照组;患者住院日显著低于对照组,4项护理措施执行率(隔离标识、手卫生、环境消毒、医务人员相关知识知晓)、病原学送检率显著高于对照组(均P<0.05)。结论集束化干预联合信息化闭环管理可有效降低EICU多重耐药菌感染发生率。  相似文献   
5.
Huo  Jia  Fu  Lijun  Jin  Mengyuan  Li  Zhaoming  Zhang  Mingzhi 《Investigational new drugs》2022,40(3):537-545
Investigational New Drugs - Background&nbsp;Chemotherapy resistance is a main reason for treatment failure in extranodal NK/T-cell lymphoma (ENKTL). Interleukin-10 (IL-10) is closely related to...  相似文献   
6.
Pharmaceutical Chemistry Journal - Cyclin-dependent kinases 4 and 6 (CDK4/6) are the core part of the cell cycle control machinery, which bind to cyclin D to regulate cell G1-S cycle conversion....  相似文献   
7.
8.
9.
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with intermediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozantinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment.  相似文献   
10.
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia...  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号